Loading…
Generate Biomedicines, Inc. is projected to rise to $16.33 by 2027, a +16% move from its current price of $14.03. GENB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $13.54 | $14.03 | $14.53 | -0.02% |
| Aug 2 | $13.34 | $14.02 | $14.75 | -0.05% |
| Aug 3 | $13.18 | $14.02 | $14.91 | -0.07% |
| Aug 4 | $13.06 | $14.02 | $15.05 | -0.09% |
| Aug 5 | $12.94 | $14.01 | $15.17 | -0.12% |
| Aug 6 | $12.84 | $14.01 | $15.28 | -0.14% |
| Aug 7 | $12.75 | $14.01 | $15.39 | -0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.75 | $14.01 | $15.39 | -0.16% |
| Week 2 | $12.24 | $13.98 | $15.97 | -0.32% |
| Week 3 | $11.87 | $13.96 | $16.43 | -0.49% |
| Week 4 | $11.55 | $13.94 | $16.82 | -0.65% |
| Week 5 | $11.28 | $13.92 | $17.17 | -0.81% |
| Week 6 | $11.04 | $13.89 | $17.49 | -0.97% |
| Week 7 | $10.82 | $13.87 | $17.79 | -1.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Generate Biomedicines, Inc. is a healthcare company focused on generative biology. It uses machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.
Its product includes GB-0895, an investigational long-acting anti-TSLP monoclonal antibody for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, a MUC16 CAR-T Cell therapy. It also develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies.
Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
Current price: $13.14 per share. Market cap: $1.68B. Rank: 2090.
The near-term forecast for 2026 lists min $11.21, avg $13.14, max $16.33 with ROI 0 and sentiment NEUTRAL.
Longer-term forecasts show rising averages and bullish momentum, with 2030 and beyond showing meaningful upside: 2030 avg $28.39 and 2050 avg $149.30, with max values reaching $48.78 and $343.39 respectively and ROIs of 116.1 and 1036.2.
A major floor 25.1% below — a decisive break under it would weaken the trend.
The nearest floor, 6.8% below — buyers have tended to step in here.
The nearest ceiling, 24.1% above — a clean break opens room to run.
A major ceiling 36.6% above — clearing it would confirm fresh momentum.
Key GENB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GENB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.47 | Buy | $13.60 | Buy |
| MA 10 | $13.66 | Buy | $13.76 | Buy |
| MA 20 | $14.46 | Sell | $14.13 | Sell |
| MA 50 | $14.23 | Sell | $14.20 | Sell |
| MA 100 | $13.59 | Buy | $13.82 | Buy |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.22 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -29.46 | Neutral |
| Williams %R (14) | -27.48 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | -1.27 | Sell |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 72.52 | Neutral |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -1.26 | Sell |
| Ultimate (7,14,28) | 45.11 | Neutral |
| Momentum (10) | 0.37 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 13.28 | Buy |
| ADX (14) | 15.53 | Neutral |
| ATR (14) | 0.44 | Info |
Near-term sentiment is NEUTRAL with RSI14 at 40. The 50-day simple moving average is $14.32.
The 30-day range runs from $10.45 to $16.52, with a current price of $13.14. There is a support at $12.38 and a resistance at $17.41, with annualized volatility of 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.21 | $14.03 | $17.50 | 0% | Neutral | |
| $11.90 | $16.33 | $24.23 | +16% | Neutral | |
| $13.19 | $19.26 | $30.47 | +37% | Bullish | |
| $16.32 | $25.09 | $41.70 | +79% | Bullish | |
| $19.54 | $31.51 | $54.53 | +125% | Bullish | |
| $19.79 | $33.34 | $59.73 | +138% | Bullish | |
| $21.31 | $37.46 | $69.21 | +167% | Bullish | |
| $21.98 | $40.23 | $76.41 | +187% | Bullish | |
| $21.22 | $40.38 | $78.66 | +188% | Bullish | |
| $24.02 | $47.52 | $94.71 | +239% | Bullish | |
| $37.09 | $82.42 | $180.56 | +487% | Bullish | |
| $79.02 | $175.61 | $403.89 | +11.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $11.21 | $14.03 | $16.44 | +0.00% |
| August 2026 | $11.43 | $13.68 | $16.97 | -2.47% |
| September 2026 | $11.28 | $13.74 | $17.47 | +0.38% |
| October 2026 | $11.42 | $14.09 | $18.27 | +2.58% |
| November 2026 | $10.96 | $13.68 | $18.02 | -2.93% |
| December 2026 | $10.38 | $13.10 | $17.50 | -4.25% |
Click any year to see its month-by-month GENB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Generate Biomedicines, Inc.'s 2026 outlook centres on $14.03, within a $11.21 to $17.50 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, GENB could reach as high as $24.23, with a base case around $16.33 and support toward $11.90 — roughly +16% from $14.03. Price action looks broadly range-bound.
Expect GENB to range from $13.19 to $30.47 through 2028. The $19.26 average target implies a +37% move from current prices. That is up +18% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The GENB price prediction for 2029 points to an average of $25.09 (low $16.32, high $41.70) — a potential gain of +79% on today's $14.03. Momentum favours further upside here.
In 2030, GENB is projected to trade between $19.54 and $54.53, averaging $31.51 — a potential gain of +125% from today's $14.03. That is up +26% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Generate Biomedicines, Inc.'s 2031 outlook centres on $33.34, within a $19.79 to $59.73 range. That is up +6% on the projected 2030 average. That marks a +138% change versus current levels. Momentum favours further upside here.
By 2032, GENB could reach as high as $69.21, with a base case around $37.46 and support toward $21.31 — roughly +167% from $14.03. Buyers look set to stay in control over this stretch.
Expect GENB to range from $21.98 to $76.41 through 2033. The $40.23 average target implies a +187% move from current prices. That is up +7% on the projected 2032 average. Momentum favours further upside here.
The GENB price prediction for 2034 points to an average of $40.38 (low $21.22, high $78.66) — a potential gain of +188% on today's $14.03. Buyers look set to stay in control over this stretch.
In 2035, GENB is projected to trade between $24.02 and $94.71, averaging $47.52 — a potential gain of +239% from today's $14.03. That is up +18% on the projected 2034 average. Momentum favours further upside here.
Generate Biomedicines, Inc.'s 2040 outlook centres on $82.42, within a $37.09 to $180.56 range. That is up +73% on the projected 2035 average. That marks a +487% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, GENB could reach as high as $403.89, with a base case around $175.61 and support toward $79.02 — roughly +11.5x from $14.03. Momentum favours further upside here.
Investing $1,000 in GENB today (≈ 71.275837 GENB) could be worth
$12,516.43
+$11,516.43 (+1152%) by 2050 · US Dollar
Based on the average projected GENB price of $175.61 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GENBwould be worth at today's price.
$1,000 invested in GENB on Feb 27, 2026 (≈ 79.051386 GENB) would be worth
$1,109.09
+$109.09 (+10.9%) today · 1.11× · US Dollar
Based on a GENB entry price of $12.65 vs. today's $14.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.83 | $1,014.46 | +1.4% |
| 1 month ago | $16.87 | $831.65 | -16.8% |
| 3 months ago | $13.15 | $1,066.92 | +6.7% |
| All time ago | $12.65 | $1,109.09 | +10.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GENB forecast.
Our base-case forecast reaches $28.00 around 2030.
Implied market cap at $28.00: $3.59B
The multi-year forecast shows bullish momentum, with the average price rising to $28.39 by 2030, $71.27 by 2040, and $149.30 by 2050.
Max values rise to $48.78 by 2030, $154.47 by 2040, and $343.39 by 2050, signaling substantial upside potential over the decade and beyond.
ROI grows to 116.1 by 2030, 442.4 by 2040, and 1036.2 by 2050. Sentiment is BULLISH from 2027 onward, underscoring a sustained optimistic outlook despite inherent uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows min $17.77, avg $28.39, max $48.78 with an ROI of 116.1 and sentiment BULLISH.
The forecast indicates bullish upside across years, with 2026 avg $13.14 (ROI 0) and 2027 avg $15.16 (ROI 15.4), rising to 2028 avg $17.58 (ROI 33.8), 2029 avg $22.66 (ROI 72.5), 2030 avg $28.39 (ROI 116.1), 2040 avg $71.27 (ROI 442.4), and 2050 avg $149.30 (ROI 1036.2).
Yes. The 2030 max is $48.78 and the 2031 max is $53.06, so the forecast allows surpassing $50 by 2031.
The 30-day range is $10.45 to $16.52; current price is $13.14. RSI is 40, SMA50 is $14.32, with support at $12.38 and resistance at $17.41; annualized volatility is 70%.
The forecast shows bullish momentum, with avg rising to $28.39 by 2030, $71.27 by 2040, and $149.30 by 2050; max values reach $48.78, $154.47, and $343.39 respectively, and ROIs reach 116.1, 442.4, and 1036.2; sentiment is BULLISH.
Generate Biomedicines, Inc. Community Discussion
0Share your Generate Biomedicines, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.